JPRN-UMIN000012089已完成未知
Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study - Treatment of MuSK antibody-positive myasthenia gravis with rituximab: an exploratory clinical study
Department of Neurology University of Tokyo, Graduate School of Medicine0 个研究点目标入组 5 人开始时间: 2013年10月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients who have severe hypersensitivity or anaphylactic reaction to rituximab or mouse-derived products. (2) Pregnant women or women of possibility of pregnancy. (3) Lactating women. (4) Patients of HBs antigen positive or patients who had HBV infection in their past. (5) Patients of HBs antigen negative and HBc antibody or HBs antibody positive, and detectable HBV-DNA. (6) Patients who have received any other experimental drug or investigational product within three months before the start of study treatment in the present study. (7) Patients who are considered inadequate for this study by Principal investigator.
研究者
相似试验
招募中
不适用
Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIGMyasthenia gravisJPRN-UMIN000015019Kansai medical university20
已完成
1 期
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia GravisMuSK Myasthenia GravisNCT05451212Cabaletta Bio7
终止
1 期
Subcutaneous Ig Maintenance Therapy for Myasthenia GravisMyasthenia GravisNCT01828294St. Louis University4
已完成
2 期
Effect of Rituximab in treatment of myasthenia gravisMyasthenia gravis.G70.0Myasthenia gravisIRCT20190324043105N2Esfahan University of Medical Sciences10
招募中
3 期
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.Ocular Myasthenia GravisNCT06342544Fondation Ophtalmologique Adolphe de Rothschild128